Filing Details
UroGen Pharma Ltd. (NASDAQ:URGN) filed a Form 8-K with the Securities and Exchange Commission on August 20, 2026, disclosing a material event.
8k filedNASDAQ:URGN
UroGen Pharma Ltd. (URGN) Reports Material Event to SEC
UroGen Pharma Ltd. (NASDAQ:URGN) filed a Form 8-K with the Securities and Exchange Commission on August 20, 2026, disclosing a material event.
At publication ·
What changed
UroGen Pharma Ltd. (NASDAQ:URGN) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- UroGen Pharma Ltd. (NASDAQ:URGN) filed a Form 8-K with the SEC on August 20, 2026, disclosing a material event that shareholders should be aware of.
- The company's stock trades at $46.80 with a market capitalization of $1.0 billion.
- The article does not specify the nature of the material event, which could involve leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance.
Market Context
UroGen Pharma Ltd.'s stock currently trades at $46.80 with a market capitalization of $1.0B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for UroGen Pharma Ltd.'s stock.
All SEC filings for UroGen Pharma Ltd. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View URGN Stock Page
Frequently Asked Questions
Where can I read URGN's SEC filings?
Browse all filings on our URGN SEC filings page.
What types of SEC filings does UroGen Pharma Ltd. file?
Public companies like UroGen Pharma Ltd. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
